10 Firms Mirror Wall Street Bloodbath

7. ADMA Biologics Inc. (NASDAQ:ADMA)

ADMA Biologics saw its share price decrease by 7.84 percent on Monday to close at $19.64 apiece as investors sold off amid an overall market pessimism and the lack of fresh catalysts to boost investing appetite.

Last week, ADMA saw a rally in its shares following announcements that it sees minimal to no impact from the ongoing trade tensions globally.

In a news release, ADMA President and CEO Adam Grossman underscored the company being a fully US-based firm, with manufacturing operations, market sales, and customer engagements conducted exclusively within the US.

“The tariffs that have been implemented on foreign goods, services, and manufacturing should have no impact on ADMA and its supply chain or production operations,” he said.

“Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience, and regulatory compliance but also aligns with increasing federal and private sector preferences for US-made products and services,” he added.

ADMA is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for treating immunodeficient patients at risk for infection and others at risk for certain infectious diseases.